BigHat Biosciences pricing
BigHat's partnering section routes to a contact form. The AbbVie collaboration was disclosed at $30 million upfront against up to $325 million in milestones. The April 2025 Eli Lilly collaboration covers up to two antibody programs with an equity investment and Catalyze360 support for BigHat's gastrointestinal cancer program, a second Lilly project in January 2026 has BigHat generating datasets for a developability model in Lilly TuneLab, and the Merck agreement covered up to three programs and was completed in August 2026.
How BigHat Biosciences pricing works
- Pricing model
- Negotiated collaboration. Revenue comes from multi year biologics discovery and engineering agreements paid through upfront payments, milestone payments as programs advance, and royalties on approved products, alongside equity investment from pharmaceutical partners. The company also funds wholly owned programs it intends to develop itself. No software license, subscription or platform access is offered.
- Implementation
- The partner installs nothing and licenses no software, so the experimental cost of a program sits inside the collaboration: BigHat runs its own synthetic biology wet lab and characterizes hundreds of variants weekly on its side of the line. In the Lilly arrangement the direction reverses in one place, with Lilly providing support to BigHat's own conjugate program through Catalyze360 while BigHat keeps full global rights.
A $75 million Series C on 24 September 2026 brought total funding to $223 million, and Amgen, Eli Lilly and Merck are investors as well as partners. The Amgen and Johnson & Johnson terms are not published.
BigHat Biosciences pricing against its alternatives
Published prices for BigHat Biosciences and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- BBigHat BiosciencesNo published price
- AAbsciNo published price
- NNabla BioNo published price
- GGenerate:BiomedicinesNot applicable
- CCradleNo published price
- IimmunitoAINo published price
- SSuperluminal MedicinesNo published price
- IIsomorphic LabsNot applicable
- PPostEraNo published price
BigHat Biosciences pricing, answered
How much does BigHat Biosciences cost?
BigHat Biosciences does not publish a price. BigHat's partnering section routes to a contact form. The AbbVie collaboration was disclosed at $30 million upfront against up to $325 million in milestones.
Does BigHat Biosciences charge an implementation fee?
The partner installs nothing and licenses no software, so the experimental cost of a program sits inside the collaboration: BigHat runs its own synthetic biology wet lab and characterizes hundreds of variants weekly on its side of the line. In the Lilly arrangement the direction reverses in one place, with Lilly providing support to BigHat's own conjugate program through Catalyze360 while BigHat keeps full global rights.